Previous 10 | Next 10 |
ZYNLONTA ® (loncastuximab tesirine-lpyl) net sales of $21.3 million in the third quarter of 2022 (+23% vs. 2Q 2022) Cash runway expected into early 2025 Company to host conference call today at 8:30 a.m. EST ADC Therapeutics SA (NYSE: ADCT) t...
Multiple presentations will highlight the clinical utility of ZYNLONTA ® (loncastuximab tesirine-lpyl) in DLBCL and Cami ( camidanlumab tesirine) in Hodgkin lymphoma ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on several of its antibody drug c...
– Companies to Leverage Lead Product Candidate from IGM’s Proprietary IgM Antibody Platform with ZYNLONTA ® for Novel Combination Therapy in Relapsed/Refractory B Cell NHL – – Phase 1 Trial Expected to be Initiated in 1Q23 – MOUN...
ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 8, 2022 at 8:30 a.m. ET to report financial results for the third quarter 2022 and provide business updates. To access the conference call, please register he...
Initial safety run‐in results from LOTIS-5 Phase 3 trial demonstrate ORR of 75% and 40% CR rate with no new safety signals Cami pivotal Phase 2 data to be highlighted in encore oral and poster presentations ADC Therapeutics SA (NYSE: ADCT) today announced that...
A committee of the European Medicines Agency (EMA) recommended the approval of ADC Therapeutics ( NYSE: ADCT ) and Swedish Orphan Biovitrum's (Sobi) Zynlonta (loncastuximab tesirine) in EU to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL). ...
Approval decision expected in 4Q 2022 ADC Therapeutics SA (NYSE: ADCT) and Swedish Orphan Biovitrum AB (Sobi®) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the mark...
Morgan Stanley downgraded ADC Therapeutics ( NYSE: ADCT ) to Equal Weight from Overweight in a research note issued on Friday. The investment bank lowered its price target to $11 from $17 on the commercial-stage biotechnology firm ADC Therapeutics ( ADCT ), citing Zyn...
ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at Morgan Stanley’s 20 th Annual Global Healthcare Conference on Tuesday, September 13 th at 11:45 a.m. ET. A live webcast of the presentat...
Upfront $120 million tranche used to finance the full settlement of existing convertible notes held by Deerfield Management Company Deerfield Management Company to take equity as part of the settlement of existing convertible notes Owl Rock to make $6.25 million equity...
News, Short Squeeze, Breakout and More Instantly...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners Funds will be used to ...
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, ef...